Therapeutic Response

PD-L1 >= 50%, Wild type ALK, Wild type EGFR, and Wild type ROS1 status confers therapeutic sensitivity to Cemiplimab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Libtayo (cemiplimab) [product information]. EMA. The European Medicines Agency (EMA) has authorized cemiplimab as a monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in >= 50% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC.